ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD prnasia
July 07, 2021Bionomics Limited is pleased to announce that it has initiated a Phase 2b trial (the ATTUNE Study) to evaluate the tablet formulation of BNC210 in patients with Post-Traumatic Stress Disorder (PTSD) with top line results expected in 1H 2023.
Pharma Sources Insight January 2025
